NCT00684411

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat T cell non-Hodgkin's lymphoma.

Detailed description

OBJECTIVES: Primary Objective To evaluate the overall response rate Secondary Objectives To assess the safety and tolerability To assess the duration of response To assess the progression free survival and overall survival STATISTICAL DESIGN: This trial will use a single stage design to differentiate a \>/= 25% response rate from a \</= 5% rate. If observed data is consistent with the alternative response rate of 25%, imatinib would be deemed clinically interesting and worthy of a larger phase II study.

Conditions

• T Cell Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Imatinib mesylate

Timeline

• Start date: 2008-06-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2008-05-26
• Last updated: 2017-01-05
• Results posted: 2017-01-05

Locations

1 site across 1 country: United States